Lynparza (olaparib)

pCPA File Number: 22575

Negotiation Status:

Active Negotiation

Indication(s):

Olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CADTH Project Number:

PC0319-000

pCPA Engagement Letter Issued:

2024-03-12

Negotiation Process Concluded:

Not Applicable